Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study
Abstract Background Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC). Six observational studies have reported CRC-specific survival outcomes in patients using aspirin after CRC diagnosis but the results from these studies have been conflicting. Using a population-based...
Main Authors: | Ronan T. Gray, Helen G. Coleman, Carmel Hughes, Liam J. Murray, Chris R. Cardwell |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4142-y |
Similar Items
-
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis
by: Ju-Li Lin, et al.
Published: (2020-07-01) -
Antiproliferative Effect of Aspirin on Colorectal Cancer Cell Line
by: Malihe Bagheri, et al.
Published: (2018-09-01) -
Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer
by: Juha P. Väyrynen, et al.
Published: (2019-06-01) -
Effects of chronic low‐dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis
by: Nadine Rohwer, et al.
Published: (2020-04-01) -
Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK – Results from micro-simulation model
by: Jorne Biccler, et al.
Published: (2021-10-01)